# A Post-marketing Surveillance to Assess Safety of Abiraterone Acetate (Zytiga) in Indian Participants With Metastatic, Castration Resistant Prostate Cancer

> **NCT02608359** · — · WITHDRAWN · sponsor: **Johnson & Johnson Private Limited**

## Conditions studied

- Prostate Cancer

## Interventions

- **DRUG:** Abiraterone Acetate

## Key facts

- **NCT ID:** NCT02608359
- **Lead sponsor:** Johnson & Johnson Private Limited
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** WITHDRAWN
- **Start date:** 2016-05-31
- **Primary completion:** 2022-05-31
- **Final completion:** 2022-05-31
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** No subjects recruited in the study
- **Last updated:** 2025-02-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02608359

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02608359, "A Post-marketing Surveillance to Assess Safety of Abiraterone Acetate (Zytiga) in Indian Participants With Metastatic, Castration Resistant Prostate Cancer". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT02608359. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*